Tumor-Infiltrating Lymphocyte Patents

Tumor-infiltrating lymphocyte (TIL) therapy patents cover expansion/manufacturing innovations; selection and enrichment innovations; gene-engineering innovations; and regimen, solid-tumor, and process innovations — with IP held by TIL-therapy companies and cancer-immunotherapy firms (in a field harvesting the patient's OWN tumor-reactive T cells that have already infiltrated their tumor, expanding them massively, and reinfusing them to attack the cancer). WHY TIL THERAPY: tumors are infiltrated by the patient's own T cells that already recognize tumor antigens (including private neoantigens), but they're too few and exhausted; TIL therapy harvests these cells from a resected tumor, EXPANDS them billions-fold ex vivo, and reinfuses them after lymphodepletion (with IL-2) — and crucially, TILs are naturally polyclonal and tumor-reactive, so they work in SOLID tumors (melanoma, and beyond), where CAR-T has largely failed. MAJOR TIL PATENT HOLDERS: IOVANCE BIOTHERAPEUTICS: lifileucel (Amtagvi) — the FIRST FDA-approved TIL therapy (advanced melanoma) — with manufacturing/expansion process IP. ACHILLES THERAPEUTICS: clonal-neoantigen-reactive TILs (selecting TILs targeting truncal/clonal neoantigens). INSTIL BIO, TURNSTONE BIOLOGICS (selected TILs), KSQ THERAPEUTICS (engineered TILs), and NCI/Rosenberg foundational work. Expansion/manufacturing, selection/enrichment, gene-engineering, and regimen/process are the core TIL patent domains — and faster manufacturing, tumor-reactive/neoantigen selection, gene-engineering, and reduced-IL-2 regimens are the open whitespace.

Expansion/rapid-expansion-protocol innovations; manufacturing-process and closed-system innovations; tumor-reactive/neoantigen-selection innovations; and enrichment and phenotype innovations represent core TIL patent domains — and expanding the right T cells, fast, consistently, at scale is the central manufacturing challenge that determines a TIL product. EXPANSION / RAPID-EXPANSION-PROTOCOL (REP) PATENTS: expanding harvested TILs billions-fold — the rapid expansion protocol using IL-2, anti-CD3 (OKT3), and feeder cells, and improvements that boost yield, fitness, and persistence while SHORTENING the process (the original process is ~22 days; shortening to a faster/'younger' TIL product is a key Iovance-type improvement) — the expansion method is core process IP. MANUFACTURING-PROCESS / CLOSED-SYSTEM PATENTS: making TIL manufacturing robust and scalable — closed/automated systems, reduced manufacturing time, consistency across patients/tumors, cryopreservation, and centralized vs decentralized manufacturing; manufacturing reliability is critical for an autologous product. TUMOR-REACTIVE / NEOANTIGEN-SELECTION PATENTS: SELECTING the TILs that actually recognize the tumor — enriching for tumor-reactive or neoantigen-reactive T cells (Achilles' clonal-neoantigen approach), using markers (CD137/4-1BB, PD-1) to identify reactive cells, and removing bystander cells; selection improves potency and is high-value. ENRICHMENT / PHENOTYPE PATENTS: enriching for desirable phenotypes (CD8, stem-like/less-differentiated 'younger' TILs that persist better) and depleting exhausted/regulatory cells. Faster/younger high-yield expansion, robust closed-system manufacturing, and tumor-reactive/neoantigen selection are the highest-value TIL process IP because manufacturing speed/consistency and selecting truly tumor-reactive cells determine product potency and feasibility.

Gene-engineering innovations; reduced-IL-2 and regimen innovations; solid-tumor and combination innovations; and persistence and armoring innovations represent additional TIL patent domains — and next-generation TILs aim to engineer the cells, cut the toxic IL-2, and broaden beyond melanoma. GENE-ENGINEERING PATENTS: engineering TILs to improve function — KNOCKING OUT checkpoint genes (PD-1) so TILs resist exhaustion, adding membrane-bound/engineered cytokines (IL-2/IL-12) for self-support, 'armoring' against the immunosuppressive tumor microenvironment, and knocking out negative regulators (KSQ's CRISPR-engineered TILs); engineered TILs are a major next-gen frontier. REDUCED-IL-2 / REGIMEN PATENTS: standard TIL therapy requires high-dose IL-2 (toxic) plus lymphodepletion — reducing or eliminating IL-2 (lower-dose regimens, engineered self-IL-2, alternative cytokine support) and optimizing lymphodepletion are valuable safety/tolerability improvements. SOLID-TUMOR / INDICATION PATENTS: extending TIL beyond melanoma to other solid tumors (lung, cervical, head-and-neck) where finding/expanding reactive TILs is harder — tumor-type-specific methods and combinations. COMBINATION / PERSISTENCE PATENTS: combining TIL with checkpoint inhibitors (anti-PD-1) or other agents, and improving in vivo persistence/engraftment. Checkpoint-knockout/armored engineered TILs, reduced-IL-2 safer regimens, and methods extending TIL to additional solid tumors are the highest-value next-gen TIL IP because engineering, reduced toxicity, and broader indications define the field's future beyond first-generation melanoma TIL.

TIL therapy startup IP strategy must navigate Iovance lifileucel/expansion patents, Achilles neoantigen-selection IP, NCI/Rosenberg foundational TIL prior art (TIL therapy was pioneered at the NCI over decades — much foundational work is older/public or government-licensed), the manufacturing-complexity (autologous, time, consistency) challenges, the IL-2-toxicity and solid-tumor-expansion realities, the autologous cost/logistics constraints, and a landscape where expansion/manufacturing, selection, engineering, and regimens are the durable assets; understand that the basic TIL approach is foundational/older (NCI), so the durable IP is in improved/faster expansion, robust manufacturing, tumor-reactive/neoantigen selection, gene-engineering, and reduced-IL-2 regimens, and that manufacturing speed/consistency, reduced toxicity, and solid-tumor breadth matter as much as patents; identify whitespace in faster manufacturing, selection, and engineered/IL-2-sparing TILs. TIL STARTUP IP STRATEGY: BASIC TIL IS FOUNDATIONAL/OLDER (NCI) — EXPANSION, SELECTION, ENGINEERING, AND REGIMEN ARE THE IP: TIL therapy was pioneered at the NCI (Rosenberg), so foundational TIL is older/often government-related — patent improved expansion, manufacturing, selection, engineering, and regimens, and check FTO/licensing on foundational and Iovance process IP; FASTER/YOUNGER EXPANSION AND ROBUST MANUFACTURING ARE HIGH-VALUE: shortening the long manufacturing process and producing fit, persistent 'younger' TILs consistently (Iovance-type improvements) is the core process moat for an autologous product; TUMOR-REACTIVE/NEOANTIGEN SELECTION IMPROVES POTENCY: selecting the truly tumor-reactive/clonal-neoantigen TILs (Achilles) raises efficacy and is defensible, high-value IP; GENE-ENGINEERING IS THE NEXT-GEN FRONTIER: checkpoint (PD-1) knockout, cytokine armoring, and CRISPR-engineered TILs (KSQ) differentiate next-generation products; REDUCING IL-2 TOXICITY IS A KEY SAFETY DIFFERENTIATOR: lower/no-IL-2 regimens and self-supporting engineered TILs improve tolerability — valuable and patentable; SOLID-TUMOR BREADTH IS TIL'S ADVANTAGE OVER CAR-T: TIL works in solid tumors — methods extending beyond melanoma (where expanding reactive TILs is harder) are high-value; AUTOLOGOUS COST/LOGISTICS ARE EXISTENTIAL: manufacturing time, cost, and per-patient logistics shape viability — process improvements matter commercially; WHEN TO PATENT: NOVEL PROCESS/SELECTION/ENGINEERING WITH MEASURED OUTCOMES: file once a method shows measured results (expansion yield/time + TIL fitness/phenotype (stem-like/CD8) + tumor-reactive fraction + response rate/persistence + IL-2 dose reduction + manufacturing success rate + indication breadth) vs. first-generation-TIL/CAR-T baselines — measured manufacturing time/yield, tumor-reactivity, and response/persistence are the critical TIL IP metrics; KEY FTO CHECKLIST: Iovance lifileucel/Amtagvi expansion/manufacturing; Achilles clonal-neoantigen-reactive selection; Instil/Turnstone/KSQ engineered/selected TIL; NCI/Rosenberg foundational TIL (older/government — FTO/licensing); rapid expansion protocol REP IL-2/OKT3/feeder; shortened/younger TIL process; closed/automated manufacturing/cryopreservation; tumor-reactive/neoantigen/CD137 selection; CD8/stem-like enrichment; PD-1 knockout/cytokine-armor/CRISPR engineering; reduced/no-IL-2 regimen + lymphodepletion; solid-tumor indication beyond melanoma; checkpoint-inhibitor combination; autologous cost/logistics.